Displaying 1 - 12 of 14
Cirrhosis & Complications
4

Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results - EASL Congress 2024

View
Cirrhosis & Complications
4

Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results - EASL Congress 2024

View
Cirrhosis & Complications
4

Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results - EASL Congress 2024

View
Cirrhosis & Complications
4

Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Displaying 1 - 12 of 14